A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Capmatinib (Primary) ; Nazartinib (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 13 Jul 2017 This trial was suspended inGermany , according to European Clinical Trials Database.
- 22 May 2017 Planned End Date changed from 31 Oct 2018 to 10 Apr 2022.
- 22 May 2017 Planned primary completion date changed from 30 Apr 2018 to 17 Jun 2021.